Drug Pricing in Canada • Aging and HIV • A Biotech Beats Goliath

CANADIAN SUPREME COURT TO RULE ON DRUG PRICING ORDER AGAINST ALEXION

Does Canada’s Patented Medicines Review Board, an arm’s length government agency, have the constitutional right to force a drug company to lower its prices and pay an “excess revenues” fine?

Alexion Pharmaceuticals finds out today whether the Supreme Court of Canada will hear its appeal of a process the review board carried out under the excessive prices provisions of Canada’s Patent Act. Alexion has failed previously in lower courts.

The process ultimately resulted in a board order requiring Alexion to slash the price it was charging for Soliris—an immensely-expensive ...